Corbus Pharmaceuticals Reports Last Subject Visit in Phase IIb Study of Lenabasum for Treatment of Cystic Fibrosis

Corbus Pharmaceuticals Holdings, Inc. announced that the last subject completed their final visit in the company’s Phase IIb JBT101-CF-002 trial of lenabasum for the treatment of cystic fibrosis.
[Corbus Pharmaceuticals Holdings, Inc]
Press Release
Bookmark

No account yet? Register

0
Share

Trump to Suspend New Visas for Foreign Scholars

With a proclamation issued on Monday, US President Donald Trump extended and expanded immigration restrictions to limit the entry of foreign workers to the United States. The move set off ripples of alarm among scientists and drew fire from experts concerned about the future of US science.
[Nature News]
Press Release
Bookmark

No account yet? Register

0
Share

Virtual Lab Tours for Recruitment and Outreach

Virtual lab tours are not new, but they have never been as common as in-person lab tours. However, the pandemic has generated strong incentives for formerly in-person lab tours to go online.
[The Scientist]
Press Release
Bookmark

No account yet? Register

0
Share

Identification of a Periodontal Pathogen and Bihormonal Cells in Pancreatic Islets of Humans and a Mouse Model of Periodontitis

Investigators determined the specific localization of Porphyromonas gingivalis in relation to mouse and human pancreatic α- and β-cells using 3-D confocal and immunofluorescence microscopy and orthogonal analyses.
[Scientific Reports]
Full Article
Bookmark

No account yet? Register

0
Share

Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic Cancer

Scientists uncovered sequence-specific changes in RNA splicing enforced by mutant p53 which enhanced KRAS activity. Mutant p53 increased expression of splicing regulator hnRNPK to promote inclusion of cytosine-rich exons within GTPase-activating proteins, negative regulators of RAS family members.
[Cancer Cell]
AbstractGraphical Abstract
Bookmark

No account yet? Register

0
Share

PharmaCyte Biotech Successfully Accelerates Development of Container Closure Integrity Test for Pancreatic Cancer Clinical Trial Product

PharmaCyte Biotech, Inc. announced that it has successfully accelerated the development of its Container Closure Integrity test– an essential component of the Stability Test required by the FDA.
[PharmaCyte Biotech Inc.]
Press Release
Bookmark

No account yet? Register

0
Share

Beta-Cell Failure in Type 2 Diabetes: Mechanisms, Markers, and Clinical Implications

Researchers discuss the progression of type 2 diabetes mellitus in the context of beta-cell failure and describe how C-peptide testing can be used to assess beta-cell function in primary care practice.
[Postgraduate Medicine]
Full Article
Bookmark

No account yet? Register

0
Share

Rapid Cancer Diagnosis and Early Prognosis of Metastatic Risk Based on Mechanical Invasiveness of Sampled Cells

Investigators evaluated the mechanical invasiveness of established breast and pancreatic cell lines and of tumor-cells from fresh, suspected pancreatic cancer tumors. The mechanical invasiveness matched the in vitro metastatic potential in cell lines as determined with Boyden chamber assays.
[Annals of Biomedical Engineering]
Abstract
Bookmark

No account yet? Register

0
Share

Mutations in the C1 Element of the Insulin Promoter Lead to Diabetic Phenotypes in Homozygous Mice

Scientists used CRISPR–Cas9 technology to generate mice with mutations in the promoter regions of the insulin I and II genes.
[Communications Biology]
Full Article
Bookmark

No account yet? Register

0
Share

Fasting Parameters for Estimation of Stimulated β-Cell Function in Islet Transplant Recipients with or without Basal Insulin Treatment

Scientists determined to what extent fasting glycemic indices could estimate stimulated β‐cell function in islet transplant recipients with and without basal insulin.
[American Journal of Transplantation]
Bookmark

No account yet? Register

0
Share

MicroRNA-181c-5p Promotes the Formation of Insulin-Producing Cells from Human Induced Pluripotent Stem Cells by Targeting smad7 and TGIF2

Investigators differentiated human induced pluripotent stem cells into insulin-producing cells in a stepwise process that recapitulated pancreas organogenesis and observed that miR-181c-5p continuously accumulated throughout the entire differentiation process.
[Cell Death & Disease]
Full Article
Bookmark

No account yet? Register

0
Share
Share